Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a clinical-stage biotech like Centessa Pharmaceuticals can feel like navigating a maze of scientific jargon and risk factors. Pipeline updates on orexin agonists, the LockBody immuno-oncology platform, and critical cash-runway disclosures are scattered across hundreds of pages. Missing one footnote could mean overlooking a trial halt or royalty obligation.
Stock Titan’s AI decodes every Centessa Pharmaceuticals quarterly earnings report 10-Q filing and annual report 10-K simplified, surfacing what matters—R&D spend by program, milestone payments, and liquidity outlook. Need to see Centessa Pharmaceuticals insider trading Form 4 transactions? You’ll also get Centessa Pharmaceuticals Form 4 insider transactions real-time as they post, while side-by-side comparisons help you understand Centessa Pharmaceuticals SEC filings explained simply. Even sudden announcements, like the 8-K material events explained when SerpinPC was discontinued, land on your dashboard seconds after they hit EDGAR.
Investors use these insights to:
- Monitor Centessa Pharmaceuticals executive stock transactions Form 4 before key data read-outs
- Track progress of ORX750 and LB101 across filings without sifting through appendices
- Compare quarter-over-quarter spending using understanding Centessa Pharmaceuticals SEC documents with AI
- Review the proxy statement executive compensation details in plain English
Whether you’re preparing a valuation model or answering, “How do I read Centessa Pharmaceuticals earnings report filing analysis?”, Stock Titan delivers the context. Real-time updates, AI-powered summaries, and historical documents ensure you never miss a disclosure again.
Centessa (NASDAQ:CNTA) Form 4 reports that Chief Business Officer Gregory M. Weinhoff exercised 10,000 options at $3.85 and immediately sold the same 10,000 ordinary shares on 06/25/2025 through a Rule 10b5-1 plan.
The shares were disposed at a weighted-average price of $13.8642, yielding roughly $139 k in gross proceeds and an implied ~$10 per-share spread. After the transactions he still owns 122,279 ordinary shares (≈8 % reduction versus post-exercise balance) and 65,000 unexercised options. The sale exceeds the 5 % materiality threshold for insider trades, making the activity noteworthy for investors tracking executive sentiment.
FAQ
What is the current stock price of Centessa Pharmaceuticals Plc (CNTA)?
What is the market cap of Centessa Pharmaceuticals Plc (CNTA)?
